Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBoston Common Asset Management, LLC
Latest Disclosed Ownership17,205 shares
Latest Disclosed Value $ 7,682,721
Boston Common Asset Management, LLC reports 6.99% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Boston Common Asset Management, LLC filed a 13F-HR form disclosing ownership of 17,205 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $7,682,721 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 7, 2026 disclosing 16,081 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 6.99% during the quarter. The current value of the position is $7,687,710 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F Vertex Pharmaceuticals COM 92532F100 17,205 1,124 6.99 7,683 5.38 0.4948
2026-05-07 2025-12-31 13F/A-1 Vertex Pharmaceuticals COM 92532F100 16,081 -24,818 -60.68 7,290 -54.49 0.4393
2026-01-15 2025-12-31 13F Vertex Pharmaceuticals COM 92532F100 19,947 -20,952 9,043 0.4582
2025-10-30 2025-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 40,899 -5,164 -11.21 16,018 -21.89 0.4480
2025-07-22 2025-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 46,063 -4,900 -9.61 20,507 -17.00 0.5749
2025-04-03 2025-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 50,963 671 1.33 24,708 22.00 0.7500
2025-01-15 2024-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 50,292 26 0.05 20,253 87,952.17 0.5896
2024-10-09 2024-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 50,266 13,008 34.91 23 35.29 0.6094
2024-07-08 2024-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 37,258 -2,061 -5.24 17 6.25 0.4475
2024-04-11 2024-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 39,319 -16,038 -28.97 16 -27.27 0.3931
2024-01-09 2023-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 55,357 -2,670 -4.60 23 10.00 0.5125
2023-10-11 2023-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 58,027 -1,210 -2.04 20 0.00 0.4814
2023-07-24 2023-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 59,237 -15,499 -20.74 21 -13.04 0.4452
2023-05-17 2023-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 74,736 -2,568 -3.32 24 4.55 0.4900
2023-01-26 2022-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 77,304 2,027 2.69 22 -99.90 1.0677
2022-10-20 2022-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 75,277 20,308 36.94 21,796 40.71 1.1422
2022-08-10 2022-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 54,969 23,085 72.40 15,490 86.16 0.7721
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 31,884 844 2.72 8,321 22.08 0.3595
2022-01-31 2021-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 31,040 -505 -1.60 6,816 19.12 0.2754
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 31,545 -169 -0.53 5,722 -10.51 0.2474
2021-08-19 2021-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 31,714 7,635 31.71 6,394 23.58 0.2749
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 24,079 24,079 5,174 0.3265
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.